Fosfomycin Trometamol (3,000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: A narrative review

Urologia Internationalis

Volumn 92, Issue 2, 2014, Pages 125-130

  Wagenlehner, Florian M E ^a   Thomas, Petra M ^b   Naber, Kurt G ^c  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b Centre d'Immunologie Pierre Fabre   (France)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Endourological interventions; Fosfomycin trometamol; Healthcare associated infections; Perioperative antibiotic prophylaxis

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; FOSFOMYCIN TROMETAMOL; NITROFURANTOIN; PLACEBO; ANTIINFECTIVE AGENT; FOSFOMYCIN;

ANTIBIOTIC PROPHYLAXIS; BLADDER TUMOR; CYSTOSCOPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL LITHOTRIPSY; HEADACHE; HEALTHCARE ASSOCIATED INFECTION; HEALTHCARE ASSOCIATED URINARY INFECTION; HUMAN; LITHOTRIPSY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SURGERY; TRANSURETHRAL RESECTION; URETEROSCOPY; URETHROTOMY; URINARY TRACT INFECTION; URODYNAMICS; ANTIBIOTIC THERAPY; BACTERIURIA; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; FOLLOW UP; HEMATURIA; INFECTION PREVENTION; MICROBIOLOGY; PERCUTANEOUS NEPHROSTOMIC LITHOTRIPSY; PERCUTANEOUS NEPHROSTOMY; PHARMACOLOGY; POSTOPERATIVE CARE; PROCEDURES; PROSTATE; PYURIA; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION OF BLADDER TUMOR; URETERORENOENDOSCOPIC LITHOTRIPSY; URETERORENOENDOSCOPY; URETHRA SURGERY; URINE CULTURE; UROLOGICAL PROCEDURE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME; URINARY TRACT INFECTIONS; UROLOGIC SURGERY;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; FOSFOMYCIN; HUMANS; LITHOTRIPSY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; URINARY TRACT INFECTIONS; URODYNAMICS; UROLOGIC SURGICAL PROCEDURES;

EID: 84900357958     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000355103     Document Type: Review

References (21)

1. Pittet D: Healthcare-associated infection: moving behind headlines to clinical solutions. J Hosp Infect 2009; 73: 293-295.
2. Gastmeier P, Kampf G, Wischnewski N, Hauer T, Schulgen G, Schumacher M, et al: Prevalence of nosocomial infections in representative German hospitals. J Hosp Infect 1998; 38: 37-49. (Pubitemid 28127504)
3. Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Çek M, Naber KG, Pickard RS, Tenke P, Wagenlehner F: Guidelines on Urological Infections. EAU Guidelines, edition presented at the 278th EAU Annual Congress, Milan 2013.
4. Cek M, Tandogdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al: Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol 2012; 63: 386-394.
5. Fosfomycin Trometamol. Product Monograph. Milan, Springer Healthcare Italia, 2012.
6. Kahlmeter G, Poulsen HO: Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.
7. Hosbul T, Ozyurt M, Baylan O, Bektore B, Ardic N, Ceylan S, et al: In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections (in Turkish). Mikrobiyol Bul 2009; 43: 645-649.
8. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S: Fosfomycin in the treatment of extended spectrum betalactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62-65. (Pubitemid 44959781)
9. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al: Community infections caused by extended-spectrum beta-lactamase- producing Escherichia coli. Arch Intern Med 2008; 168: 1897-1902.
10. Periti P, Novelli A, Reali EF, Del Bono GP, Fontana P: Prophylactic chemotherapy with fosfomycin trometamol salt in transurethral prostatectomy. A controlled clinical trial; in Neu HC, Williams JD (eds): New Trends in Urinary Tract Infections. The Single-Dose Therapy International Symposium, Rome, January 1987. Basel, Karger, 1988, pp 207-233.
11. Periti P, Novelli A, Reali EF, Lamanna S, Fontana P: Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol 1987; 13(suppl 1):122-131. (Pubitemid 17233798)
12. Di Silverio F, Cruciani E, Ferrone G, Prencipe MG, Lauretti S, Fini D: Evaluation of fosfomycin trometamol in the prevention of urinary tract infections after ESWL and ureteropyeloscopy; in Neu HC, Williams JD (eds): New Trends in Urinary Tract Infections. The Single-Dose Therapy International Symposium, Rome, January 1987. Basel, Karger, 1988, pp 329-332.
13. Baert L, Billiet I, Vandepitte J: Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection 1990; 18(suppl 2):S103-S106. (Pubitemid 20338581)
14. Di Silverio F, Ferrone G, Carati L: Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection 1990; 18(suppl 2):S98-S102. (Pubitemid 20338580)
15. Selvaggi FP, Battaglia M, Grossi FS, Disabato G, Cormio L: Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection 1992; 20(suppl 4):S321-S324. (Pubitemid 23081505)
16. Nicoletti G, Nicolosi D, Schito GC, Varaldo M, Carati L: Fosfomycin trometamol in prophylaxis of bacteriuria associated with transurethral diagnostic procedures. Urogynaecologia 1994; 8: 123-134.
17. Szopinski T, Antoniewicz AA, Borówka A: The prophylactic use of phosphomycin in endoscopic procedures associated urinary tract infections (in Polish). Urol Pol 2002; 55: 1-7.
18. Jimenez-Pacheco A, Lardelli Claret P, Lopez Luque A, Lahoz-Garcia C, Arrabal Polo MA, Nogueras Ocana M: Randomized clinical trial on antimicrobial prophylaxis for flexible urethrocystoscopy. Arch Esp Urol 2012; 65: 542-549.
19. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-e120.
20. Wagenlehner FME, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensiek W, Watermann D, Naber KG: Epidemiology, diagnostics, therapy and management of uncomplicated bacterial community acquired urinary tract infections in adults. Short version 17 June 2010. Chemother J 2011; 20: 158-168.
21. Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.